



US009034376B2

(12) **United States Patent**
Wright et al.(10) **Patent No.:** **US 9,034,376 B2**(45) **Date of Patent:** ***May 19, 2015**(54) **PHARMACEUTICAL FORMULATION**
CONTAINING GELLING AGENT(2013.01); **A61K 47/38** (2013.01); **A61K 47/36**
(2013.01); **A61K 47/10** (2013.01); **A61K 45/06**
(2013.01); **A61K 31/192** (2013.01); **A61K**
9/1652 (2013.01); **A61K 47/26** (2013.01)(71) Applicants: **Purdue Pharma L.P.**, Stamford, CT
(US); **The P.F. Laboratories, Inc.**,
Totowa, NJ (US); **Purdue**
Pharmaceuticals L.P., Wilson, NC (US)(58) **Field of Classification Search**

None

See application file for complete search history.

(72) Inventors: **Curtis Wright**, Rockport, MA (US);
Benjamin Oshlack, Boca Raton, FL
(US); **Christopher Breder**, Bethesda,
MD (US)

(56)

References Cited

U.S. PATENT DOCUMENTS

3,065,143	A	11/1962	Christenson et al.
3,133,132	A	5/1964	Loeb et al.
3,173,876	A	3/1965	Zobrist et al.
3,260,646	A	7/1966	Paulsen et al.
3,276,586	A	10/1966	Rosaen
3,541,005	A	11/1970	Strathmann et al.
3,541,006	A	11/1970	Bixler et al.
3,546,876	A	12/1970	Fokker et al.
3,845,770	A	11/1974	Theeuwes et al.
3,916,889	A	11/1975	Russell
3,965,256	A	6/1976	Leslie
3,980,766	A	9/1976	Shaw et al.
4,063,064	A	12/1977	Saunders et al.
4,070,494	A	1/1978	Hoffmeister et al.
4,088,864	A	5/1978	Theeuwes et al.
4,160,020	A	7/1979	Ayer et al.
4,175,119	A	11/1979	Porter
4,200,098	A	4/1980	Ayer et al.

(Continued)

(21) Appl. No.: **14/460,134**(22) Filed: **Aug. 14, 2014**(65) **Prior Publication Data**

US 2014/0357657 A1 Dec. 4, 2014

Related U.S. Application Data(63) Continuation of application No. 14/255,502, filed on
Apr. 17, 2014, now Pat. No. 8,871,265, which is a
continuation of application No. 13/726,324, filed on
Dec. 24, 2012, which is a continuation of application
No. 13/349,449, filed on Jan. 12, 2012, now Pat. No.
8,337,888, which is a continuation of application No.
12/653,115, filed on Dec. 8, 2009, now abandoned,
which is a continuation of application No. 10/214,412,
filed on Aug. 6, 2002.(60) Provisional application No. 60/310,534, filed on Aug.
6, 2001.(51) **Int. Cl.**

A61K 9/20	(2006.01)
A61K 31/167	(2006.01)
A61K 9/00	(2006.01)
A61K 31/439	(2006.01)
A61K 31/485	(2006.01)
A61K 47/38	(2006.01)
A61K 47/36	(2006.01)
A61K 47/10	(2006.01)
A61K 45/06	(2006.01)
A61K 31/192	(2006.01)
A61K 9/16	(2006.01)
A61K 47/26	(2006.01)

(52) **U.S. Cl.**CPC **A61K 31/167** (2013.01); **A61K 9/2013**
(2013.01); **A61K 9/205** (2013.01); **A61K**
9/2054 (2013.01); **A61K 9/0002** (2013.01);
A61K 31/439 (2013.01); **A61K 31/485**

FOREIGN PATENT DOCUMENTS

EP	0318262	A1	5/1989
EP	0661045		7/1995

(Continued)

OTHER PUBLICATIONS

Paragraph IV Patent Certification Notice for ANDA 202434 (2011).
Paragraph IV Patent Certification Notice for ANDA 203235 (2011).
Paragraph IV Patent Certification Notice for ANDA 202372 (2011).
Paragraph IV Patent Certification Notice for ANDA 202483 (2011).
Paragraph IV Patent Certification Notice for ANDA 202762 (2011).
Paragraph IV Patent Certification Notice for Amendment to ANDA
202762 (2011).

(Continued)

Primary Examiner — Robert A Wax*Assistant Examiner* — Olga V Tcherkasskaya(74) *Attorney, Agent, or Firm* — Lowenstein Sandler LLP

(57)

ABSTRACTDisclosed in certain embodiments is a controlled release oral
dosage form comprising a therapeutically effective amount of
a drug susceptible to abuse together with one or more phar-
maceutically acceptable excipients; the dosage form further
including a gelling agent in an effective amount to impart a
viscosity unsuitable for administration selected from the
group consisting of parenteral and nasal administration to a
solubilized mixture formed when the dosage form is crushed
and mixed with from about 0.5 to about 10 ml of an aqueous
liquid; the dosage form providing a therapeutic effect for at
least about 12 hours when orally administered to a human
patient.**19 Claims, No Drawings**